Exclusion criteria
cataract, amblyopia, ocular or non-ocular disorder, choroideremia
AMBLYOPIA, DISEASE, CATARACT, COLLAPSE, CHOROIDEREMIA
Participants were not eligible for study participation if they had a history of amblyopia in the eligible eye or were unwilling to use barrier contraception methods or abstain from sexual intercourse for 3 months if treated with timrepigene emparvovec, as is standard for gene therapy trials. Furthermore, participants should not have had a previous intraocular surgery in the study eye within 3 months of the first visit or any significant ocular or non-ocular disorder that, in the opinion of the investigator, might put the participant at risk, influence the results of the study or affect the ability of the individual to participate in the study. This includes, but was not limited to, individuals with a contraindication to an oral corticosteroid (for example, prednisolone/prednisone), with a clinically significant cataract and who, in the clinical opinion of the investigator, was not an appropriate candidate for subretinal surgery. To be eligible for participation, individuals should also not have taken part in another research study involving an investigational product in the past 12 weeks or received a gene or cell therapy at any time in the past.Individuals with advanced choroideremia can have variable BCVA readings when the disease causes partial collapse of the fovea—a concept referred to as ‘foveal splitting’ by the investigators. For this reason, participants were recruited from the natural history of choroideremia (NIGHT) study group (ClinicalTrials.gov: 